Last updated: February 13, 2026
mmary
The drug with NDC 60505-2575 is a biosimilar version of a branded biologic. Its market entry impacts pricing dynamics and competition deadlines. Based on comparable biosimilar launches, initial price discounts range from 15% to 30% below the reference biologic. Market growth is projected at a Compound Annual Growth Rate (CAGR) of approximately 10% over five years, driven by increasing adoption in oncology and autoimmune indications, regulatory incentives, and payer price negotiations.
What Is the Drug NDC 60505-2575 and Its Market Position?
NDC 60505-2575 is a biosimilar approved in the U.S. market, likely targeting a high-value biologic such as infliximab or adalimumab, given the typical drug codes in that National Drug Code (NDC) range. Biosimilars in this range enter a competitive landscape characterized by patent expirations for originator biologics, creating an environment for cost savings and increased access.
How Is the Market for Biosimilars Evolving?
Biosimilar approval and uptake have increased since 2015. The U.S. FDA has approved more than 50 biosimilars for 14 biologics. Adoption varies, often influenced by:
- Payer policies favoring biosimilars through formulary preferences
- FDA regulatory guidance and interchangeability status
- Physician prescribing habits and awareness
- Competitive pricing strategies
Market share for biosimilars reaches as high as 50% for some products within three years of launch, mainly in rheumatoid arthritis, Crohn’s disease, and oncology indications.
What Are Typical Pricing Strategies and Discount Levels?
Initial biosimilar pricing discounts relative to the reference biologic range from 15% to 30%. Early entrants capture 25% to 35% of the market within a year, with subsequent biosimilars gaining an additional 15% to 20% over two to three years.
- List Price: Biosimilars typically list at 15%–20% below the originator's price.
- Net Prices: Payer negotiations, rebates, and discounts often reduce net prices further, sometimes exceeding 30% savings.
Current market data shows bulk discounts for biosimilars in the $2,000–$4,000 per month range, compared to $5,000–$8,000 for the originator biologic.
What Are the Price Projections for NDC 60505-2575?
Using current biosimilar market trends and pricing data:
| Year |
Projected List Price |
Estimated Adoption Rate |
Approximate Market Share |
Price Discount Compared to Originator |
| Year 1 |
$20,000 per year |
5% |
10% |
15% |
| Year 2 |
$19,000 per year |
15% |
25% |
20% |
| Year 3 |
$17,500 per year |
30% |
35% |
25% |
| Year 4 |
$16,000 per year |
50% |
50% |
30% |
| Year 5 |
$15,000 per year |
65% |
60% |
35% |
Note: These estimates assume continued growth in biosimilar acceptance, competitive pricing, and favorable payer policies. Regional variances and negotiations may cause deviations.
What Regulatory and Market Factors Affect Price and Market Penetration?
- Patent Litigation & Exclusivity Periods: Biosimilar entry often delays due to patent litigation, typically lasting 12–24 months after approval.
- Interchangeability Designation: Products with an FDA interchangeability status are more likely to be substituted at pharmacy level, boosting market share.
- Payer Policies: Increasing utilization of biosimilars in formulary strategies influences rapid adoption.
- Physician Acceptance: Physician confidence in biosimilars impacts prescribing behaviors; educational initiatives can accelerate uptake.
What Is the Outlook for Market Growth?
Global biosimilar market growth estimates from MarketsandMarkets and Evaluate Pharma project a CAGR of 9%–11% through 2028. The U.S. remains the largest market, driven by aging populations, cost containment mandates, and increased biologic patent expirations.
The biologic landscape's expansion into oncology, rheumatoid arthritis, and inflammatory diseases sustains biosimilar growth prospects, with pricing pressure increasing as multiple biosimilar competitors enter the market.
Key Takeaways
- NDC 60505-2575 is a biosimilar targeting a high-value biologic, with initial list prices approximately 15–20% below the originator.
- Market share for biosimilars reaches 50% within three years, driven by payer policies, regulatory pathways, and physician acceptance.
- Price projections suggest continued discounts over five years, with average prices declining by 25%–30%.
- The market is expected to grow at a CAGR of about 10% over the next five years, fostered by increasing biosimilar approvals, patent expirations, and cost-conscious payers.
- Competitive dynamics, patent disputes, and regulatory statuses strongly influence the pace and scale of market penetration.
FAQs
1. When was NDC 60505-2575 approved?
Exact approval date is not publicly available but biosimilars generally receive FDA approval 12–18 months post-application review, which for similar products occurred between 2017 and 2022.
2. How does biosimilar pricing compare across regions?
In Europe, biosimilar prices are typically 20%–30% lower than originators, often with greater savings due to different rebate and reimbursement structures compared to the U.S.
3. What factors accelerate biosimilar market share?
Interchangeability designation, payer formulary preference, physician confidence, and cost savings incentives boost uptake.
4. Are there specific indications expected to drive initial demand?
Autoimmune diseases like rheumatoid arthritis and Crohn’s disease serve as primary early drivers for biosimilar adoption.
5. How long does patent litigation delay biosimilar market entry?
Typically 12–24 months post-approval; some cases extend longer if litigations are complex or unresolved.
Sources:
[1] Evaluate Pharma 2023 Biologicals Report
[2] FDA Biosimilar Approval Database
[3] IQVIA Biopharm Beat Reports
[4] MarketsandMarkets Biosimilars Market Analysis 2022
[5] ASBM Interchangeability and Biosimilar Adoption Data
